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The urachus is a tubular structure that connects the bladder to the allantois in the embryonic development, involuting after the
third trimester. The urachus carcinoma is an extremely rare tumor that accounts for <1% of all bladder cancers. We report a case
of a 46-year-old woman, with no past medical history, complaining of hematuria with 6-month duration and a physical exam
and an abdominal computed topographic scan revealing an exophytic mass of 6.8 cm longer axis that grew depending on the
anterior bladder wall, invading the anterior abdominal wall. Cystoscopy detected mucosal erosion. The biopsy showed structures
of adenocarcinoma of enteric type. The surgical specimen showed urachus adenocarcinoma of enteric type with stage IVA in the
Sheldon system and stage III in the Mayo system. This case has a 3-year follow-up without disease recurrence.
1. Introduction
Theurachus is a tubular structure that connects the bladder to
the allantois in the embryonic development, involuting after
the third trimester, into a fibromuscular tract or closed canal
between the dome of urinary bladder and the umbilicus.
Urachal remnant may persist in approximately 32% of adults
[1], consisting of a tubular or cystic structure lined by epithe-
lium, surrounded by connective tissue and musculature, in
the complete form.
The urachus carcinoma accounts for <1% of all bladder
cancers [2, 3]. It is a malignant epithelial neoplasm arising
from urachal remnants. Ninety percent of them are adeno-
carcinomas [4], believed to evolve from intestinal metaplasia
of the epithelial component [1], accounting for 10% of the
bladders adenocarcinoma [5]. Nonglandular neoplasms can
be urothelial, squamous cells, neuroendocrine, and mixed
type [6].
To date, because of its rarity, there is some inconsistency
and no consensus in the literature about the nomenclature,
the diagnostic criteria, the staging system to use, and the best
therapeutic options.
We report a case of 46-year-old woman with an urachal
carcinoma and do a brief literature review about this
extremely rare entity.
2. Case Report
A 46-year-old woman with no past medical history was
referred to our hospital with complaints of hematuria with 6-
month duration. No other complaint was reported. Physical
exam and an abdominal computed topographic (CT) scan
revealed an exophytic mass with 6.8 cm longer axis that grew
depending on the anterior bladder wall, invading the anterior
abdominal wall. Cystoscopy detected mucosal erosion, and
a vesical biopsy was performed showing adenocarcinoma
structures of enteric type in the bladderwall, partially covered
by urothelium with reactive changes. A thoracic CT scan and
a virtual colonoscopy were performed showing no obvious
sites of distant metastases, or primary disease of the bowel.
Based on these findings, a decision was made to operate.
The surgical approach adopted was a pelvic exenteration with
anterior resection of the abdominal rectum and navel, with
pelvic lymphadenectomy and ureteroileostomy of Bricker
(Figure 1).
The bladder, uterus, ovaries, navel, subcutaneous tissue,
and rectus abdominis muscle composed the complex sur-
gical piece. The bladder with 4 cm internal diameter had
a thickened wall in its upper half (3.5 cm thickness) due
to diffuse infiltration by whitish and compact tumor with
7.5 cm greatest diameter, centered between the bladder and
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Figure 1: Intraoperative view.
abdominal wall (which was infiltrated to the level of the
subcutaneous tissue). Uterus and ovaries were unchanged
(Figure 2).
Samples were fixed in 10% neutral-buffered formalin and
embedded in paraffin. Paraffin sections were stained with
standard routine stains. Immunostains were performed with
avid-biotin-peroxidase method.
The histology revealed an adenocarcinoma of enteric
type with poorly differentiated areas and areas with focal
mucinous differentiation (Figure 3). The tumor was accom-
panied by intense inflammatory and desmoplastic reaction.
The surgical retropubic plan intersected neoplastic tissue. All
the remaining surgical margins were free. Metastasis to a
single regional lymph node was identified. The immunos-
tains revealed cytokeratin 20 (CK20) and CDX2 expression,
absence of expression for cytokeratin 7 (CK7) and cytokeratin
34𝛽E12 (34𝛽E12), and only focal nuclear staining for 𝛽-
catenin (Figures 4 and 5).
The patient underwent then 12 cycles of chemotherapy
with FOLFOX (5-FU, leucovorin, and oxaliplatin) and pelvic
radiotherapy.
The patient has a 3-year clinical and imagiologic follow-
up, with no evidence of disease recurrence.
3. Discussion
Urachus carcinoma is a rare entity, with quite limited pub-
lished studies. Hue and Jacquin published the first case report
in 1863. In the 1950s Wheeler and Hill proposed the initially
accepted diagnostic criteria for the urachus carcinoma. The
criteria have undergone modifications and are still contro-
versial; even so, most investigators accepted the proposed
criteria by Sheldon et al. [7] and Mostofi et al. [8] that were
(a) tumor in the dome of the bladder, (b) absence of cystitis
cystica and cystitis glandularis, (c) predominant invasion of
the muscularis or deeper tissues with a sharp demarcation
between the tumor and surface bladder urothelium that is
free of glandular or polypoid proliferation, (d) presence of
urachal remnants within the tumor, (e) extension of tumor
into the bladderwall with involvement of the space of Retzius,
anterior abdominal wall, or umbilicus, and (f) no evidence
of a primary neoplasm elsewhere. However, these criteria
were considered somewhat restrictive by some studies [9–
11]. A new somewhat broader set of criteria adapted from
Gopalan et al. was published in the 2016 World Health
Organization (WHO) blue book for the diagnosis of urachal
adenocarcinoma which are (a) location of the tumor in
the bladder dome and/or anterior wall, (b) epicenter of
carcinoma in the bladder wall, (c) absence of widespread
cystitis cystica and/or cystitis glandularis beyond the dome
and anterior wall, and (d) absence of a known primary tumor
elsewhere.
The case presented here illustrated the following features:
the tumor was located in the anterior wall and in the bladder
dome, the epicenter of the tumor was in the bladder wall,
there was absence of cystitis cystica or cystitis glandularis,
and the investigations carried out did not reveal any primary
tumor elsewhere, thereby fulfilling all the WHO criteria
for the diagnosis of urachal adenocarcinoma. It showed
also a sharp demarcation between the tumor and surface
bladder urothelium that was free of glandular and polypoid
proliferation. And finally the presence of urachal remnant
explained by the tumor extent was not documented. This
feature is helpful for the diagnosis but its absence does not
preclude the urachal origin.
It was a glandular tumor, with enteric differentiation,
being considered an enteric adenocarcinoma. The generally
accepted histological subtyping of urachal adenocarcinoma
is of enteric, mucinous, signet ring cell, mixed type or not
otherwise specified. Most of the adenocarcinomas are of
mucinous type [1]. According to same authors, there is no
association between prognosis and tumor type [11].
Immunohistochemically (IC), the adenocarcinoma of the
present case, expressed CK20 and CDX2, was negative for
CK7 and 34𝛽E12 and presents only very focal nuclear staining
for 𝛽-catenin. These IC results support the diagnosis of
urachal origin. The urachal adenocarcinoma is generally
positive for CK20 and CDX2, CK7 in 60% of the cases, and
34𝛽E12 in 66% but only very focally [1, 11]; nuclear staining
with 𝛽-catenin occurs in 6% [1], normally showing only
cytomembranous staining. The diffuse nuclear staining of 𝛽-
catenin and the absence of expression of CK7 favor colonic
origin. The gastrointestinal tract markers claudin-18 and Reg
IV can also be expressed by the urachal adenocarcinomas [1].
The molecular alterations reported in 40% of urachal
adenocarcinomas are microsatellite instability and mutations
of KRAS at codon 12 [6]. The patients with the KRAS muta-
tions have a better overall survival [6]. No other molecular
alterations were reported, like BRAFmutations, EGFRmuta-
tions, or ALK rearrangements.
The differential diagnosis of this case, like the majority
of urachal adenocarcinomas, is between adenocarcinomas
of two different origins, primary vesical or metastatic colon
tumor. For the exclusion of vesical origin the gross features,
the epicenter of the tumor in the bladder wall, a sharp
demarcation between the tumor and the surface bladder
urothelium, and the absence of carcinoma in situ or extensive
glandular metaplasia of the adjacent urothelium must be
taken into account. For the exclusion of the colonic origin, a
clinical exploration and the results of immunostains are very
important.
There are several staging systems for urachal carcinomas.
The most widely accepted one is the staging proposed by
Sheldon et al. (Table 1) and the Mayo system (Table 2),
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Figure 2: Macroscopic aspects: (a) superior view; (b) sagittal section.
(a) (b) (c)
Figure 3: Histologic features of the tumor: (a) urothelium surface; (b) glandular differentiation; (c) areas of lesser differentiation.
(a) (b)
Figure 4: Immunostains: (a) CK20 positive staining in the tumor and negative staining in the overlying urothelium; (b) CK7 negative staining
in the tumor and positive staining in the urothelium.
proposed by Ashley et al., but their relevance still needs
validation by larger series.
Most urachal carcinomas are diagnosed in advance stages
[9], being associated with a poor prognosis. The overall
outcome falls around 45% to 50%, 5-year survival [2, 3, 5,
12]. In comparison with bladder urothelial carcinoma, in
similar stages, urachal carcinoma has a better survival rate
[9].There are some independent predictor factors, considered
by some studies to influence the outcome [2, 12, 13], that are
tumor spread outside of bladder to adjacent organs and/or
abdominal wall, the presence of metastasis, and residual
disease.
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Figure 5: Immunostains: (a) CDX2 positive staining in the tumor; (b) 𝛽-catenin negative nuclear staining in the majority of the tumor.
Table 1: Sheldon staging system.
I No invasion beyond the urachal mucosa
II Invasion confined to the urachus
III Local extension into
IIIA Bladder
IIIB Abdominal wall
IIIC Peritoneum
IIID Viscera other than the bladder
IV Metastasis to
IVA Regional lymph nodes
IVB Distant sites
Table 2: Mayo staging system.
I Confined to the urachus and/or bladder
II Extension beyond the muscular layer of the urachusand/or bladder
III Infiltration to the regional lymph nodes
IV Infiltration to nonregional lymph nodes or otherdistant sites
Our case was staged by Sheldon system as stage IVA and
stage III by Mayo system. This case despite advance stage
of the disease, lymph node metastasis, and the presence of
neoplastic structures in surgical margin, has a 3-year clinical
and imagiologic follow-up without disease recurrence.
The recommended treatment for nonmetastatic cases is
surgery. Partial or radical cystectomy has similar oncologic
results [4]. En bloc resection with complete removal of
urachal remnant and the umbilicus should be the surgery
performed for prolonged survival [4]. The effective role of
neoadjuvant or adjuvant chemotherapy is still to be proven
[1]; however there are some reports of metastatic cases,
with response to FOLFOX chemotherapeutic regimen [1].
Radiotherapy was performed in our case because of the
positive surgical margin.
4. Conclusion
In summary, we present a case of urachal adenocarcinoma,
of enteric type, with advance stage disease, with some
negative predictor factors like lymph node metastasis, and
with positive surgicalmargin.The patient underwent surgical
resection of the tumor, chemotherapy, and radiotherapy and
has a 3-year follow-up free of recurrence of disease. In
the literature review there is a new set of criteria adapted
from Gopalan et al. and published in the 2016 WHO blue
book, and the most accepted staging systems are still the
Sheldon and Mayo systems. Relatively to the outcome there
are some studies reporting better survival rates of urachal
adenocarcinoma comparing with the urothelial carcinoma.
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